Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio
1.10.2019 09:00:00 EEST | Business Wire | Press release
Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI globally, in all countries where the drug was approved under an exclusive license from CTI BioPharma.
“The acquisition of PIXUVRI is an important step towards Servier’s long-term strategy to become a key player in oncology. Within oncology, one of our key focuses is hematology, and we now have two medicines that are marketed globally alongside a strong and innovative pipeline of drug candidates which includes CAR-T therapies,” said Claude Bertrand, Executive VP, Global Head of R&D at Servier. “As part of our strategy, we are committed to invest 50% of our R&D budget in oncology.”
Non-Hodgkin lymphoma (NHL) is a blood cancer that affects the lymphatic system, it can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.1 Globally there are over 500,000 new cases of NHL a year; it is both the 11th most commonly diagnosed cancer and cause of cancer death.2
“We have a strong commitment to providing effective solutions for patients living with cancer. PIXUVRI is an effective treatment that received standard European marketing authorization in June, and today marks a new step towards achieving Servier’s long term goals. We will ensure that patients will continue to have access to PIXUVRI”, said Eric Falcand, VP, Global Head of Business Development & Licensing at Servier. “We are continuing to strengthen our oncology portfolio through our R&D efforts and strategic alliances.”
#ENDS#
About PIXUVRI (pixantrone)
PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.3 PIXUVRI is indicated in the European Union as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.3 PIXUVRI is also approved in Iceland, Israel, Liechtenstein, Myanmar, Norway, Pakistan, Russia and Ukraine.
PIXUVRI is mentioned in the ESMO guidelines as an anthracycline-like drug with reduced cardiotoxicity, which demonstrated some efficacy in heavily treated patients.4
More detail is available in the summary of the European public assessment report (EPAR) on the EMA website at www.ema.europa.eu.
About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics and immune targeted therapies, to deliver life-changing medicines to patients.
More information: www.servier.com
Follow us on Social Media: LinkedIn I Facebook I Twitter
1 Cancer Research UK. What is NHL cancer. Available at http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/what-is-lymphoma. Last accessed September 2019.
2 World Health Organisation. Globocan 2018. Non-Hodgkin lymphoma. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/34-Non-hodgkin-lymphoma-fact-sheet.pdf. Last accessed September 2019.
3 European Medicines Agency. Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/pixuvri-epar-product-information_en.pdf. Last accessed September 2019.
4 Tilly H et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2015). Volume 26 (suppl 5); v116-v125. Available at: http://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma. Last accessed September 2019.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190930005875/en/
Contact information
Servier Media Relations
Sonia Marques
sonia.marques@servier.com
Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Jean-Clément Vergeau
jean-clement.vergeau@servier.com
Tel. +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75 96
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Impartner Recognized as a Leader in G2 Summer 2026 Enterprise Grid® for Partner Relationship Management4.6.2026 16:00:00 EEST | Press release
Impartner, the world’s leading partner revenue orchestration platform, today announced it has been named a Leader in the G2 Summer 2026 Enterprise Grid® Report for Partner Relationship Management (PRM). The recognition underscores Impartner’s strong customer validation and continued momentum among enterprise organizations managing large-scale partner ecosystems and indirect sales channels. In the Summer 2026 report, Impartner earned Leader status based on strong customer satisfaction and adoption across organizations operating at scale. G2’s findings show a 4.5 out of 5-star rating from more than 500 verified reviews, with 91% of users indicating they would recommend the platform. Customers gave high marks for key capabilities, including Role-Based Permissions, Deal Management, and Content Repository, with Ease of Doing Business With as the highest-rated category, reflecting a strong user experience driven by a dedicated customer success team, responsive support, and a commitment to in
Tsuno Rice Fine Chemicals: Comparative Absorption Study of Rice Bran-Derived “Rice Magnesium” Reveals New Insights into Its Gradual, Sustained Absorption Profile4.6.2026 16:00:00 EEST | Press release
Tsuno Rice Fine Chemicals Co., Ltd. announced findings from an in-house human study showing that its proprietary rice bran-derived ingredient, “Rice Magnesium,” delivers gradual, sustained magnesium absorption compared with other magnesium sources. The results suggest potential benefits for sleep maintenance, muscle fatigue management during prolonged exercise, and gentler digestive tolerance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604576648/en/ Tsuno Rice Fine Chemicals: Differences in Absorption Among Magnesium Supplements Product Name: Rice Magnesium Most magnesium ingredients currently available on the market are mineral-derived. In contrast, Rice Magnesium is a rare plant-based magnesium ingredient sourced from rice bran, developed through Tsuno’s long-standing rice bran research. Composition: Magnesium phosphate Source Material: Japanese rice bran Study Background Magnesium is an essential mineral involved i
CSC Adds .BRAND Advisory and Domain Security Services to CrowdStrike Marketplace through Expanded Partnership4.6.2026 16:00:00 EEST | Press release
CSC, the world's leading enterprise-class domain registrar and online brand protection provider, today announced that its .BRAND services are now available on the CrowdStrike Marketplace. Building on CSC’s existing integration with the CrowdStrike Falcon® platform, this new listing provides enterprises with advanced domain advisory and security support to help them navigate the ICANN New gTLD Program application window, open now until August 12, 2026. As artificial intelligence (AI) drives increased activity across digital assets and domain name system (DNS) infrastructure, managing domain portfolios is a key part of enterprise cybersecurity. With CSC’s .BRAND services available on the CrowdStrike Marketplace, customers can centralize control and reduce reliance on third-party domains. By establishing a DNS trust anchor with centralized authentication aligned to zero-trust principles, organizations that use .BRAND top-level domains (TLDs) gain verified first-party assets that help miti
Fortegra Appoints Mark Rattner as President4.6.2026 16:00:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra" or the "Company"), a global specialty insurer and part of DB Insurance Co., Ltd., today announced the appointment of Mark Rattner as President. Mr. Rattner, who previously served as Executive Vice President and Chief Underwriting Officer, Insurance, brings a decade of Fortegra leadership and long-standing relationships with reliable distribution partners to his expanded role. Drawing on disciplined underwriting expertise built over a career spanning more than three decades, Mr. Rattner is focused on delivering the highest value and consistent results to the agents and brokers the company serves. His appointment reflects Fortegra’s continued investment in the people and partnerships that drive long-term, sustainable profitability. “Mark has been central to building Fortegra into the company it is today. His industry experience, knowledge, and trade craft make him the right person for this role. As we continue to evolve, Mark will enhance our partners
New Study Reveals the True Environmental Impact of Periodontal Disease – And What You Can Do About It4.6.2026 15:33:00 EEST | Press release
Today P&G Oral Care announces the release of a new, first-of-its kind LCA study published in the Journal of Dentistry finds managing advanced periodontal disease can be associated with up to ~10× higher environmental impact compared with maintaining periodontal health through at-home prevention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601115251/en/ Oral-B iO9 Black The peer-reviewed paper, titled “Quantifying the Environmental Impact Potential from Periodontal Health to Disease: Findings from a Life Cycle Assessment Study,” for the first time quantifies the environmental burden associated with the presence of periodontal disease, its progression and the associated clinical care. It was developed by sustainability and oral health experts in collaboration with Procter & Gamble (P&G). The ISO 14040/14044–compliant research applies a whole-system life cycle assessment (LCA) lens to oral healthcare, quantifying environm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom